These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 28432713)

  • 1. Case of recurrent severe cellulitis and cutaneous candidiasis during psoriasis treatment with ustekinumab.
    Miyachi H; Nakamura Y; Wakabayashi S; Iwasawa MT; Oikawa A; Watanabe A; Matsue H
    J Dermatol; 2017 Aug; 44(8):e206-e207. PubMed ID: 28432713
    [No Abstract]   [Full Text] [Related]  

  • 2. Wells' Syndrome Induced by Ustekinumab.
    Rozenblat M; Cohen-Barak E; Dodiuk-Gad R; Ziv M
    Isr Med Assoc J; 2019 Jan; 21(1):65. PubMed ID: 30685913
    [No Abstract]   [Full Text] [Related]  

  • 3. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.
    Fioranelli M; Roccia MG; Lotti T
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28508536
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety of ustekinumab in severe psoriasis with chronic hepatitis B.
    Raymundo AR; Facin AP; Silva de Castro CC; Faria AR
    Indian J Dermatol Venereol Leprol; 2016; 82(3):326-8. PubMed ID: 27088944
    [No Abstract]   [Full Text] [Related]  

  • 5. Cutaneous protothecosis in a patient on ustekinumab for psoriasis.
    Jenkinson H; Thelin L; McAndrew R; Jones KM; Talbott LB; Diven D
    Int J Dermatol; 2018 Oct; 57(10):1246-1248. PubMed ID: 29603193
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe disseminated Nocardia infection associated with ustekinumab treatment for psoriasis.
    Couture-Cossette A; Morand M; Vinh DC; Gratton M; Martin P
    Br J Dermatol; 2019 Jul; 181(1):194-195. PubMed ID: 30657168
    [No Abstract]   [Full Text] [Related]  

  • 7. Exacerbation of infliximab-induced paradoxical psoriasis after ustekinumab therapy.
    Suh HY; Ahn JY; Park MY; Youn JI
    J Dermatol; 2018 Mar; 45(3):332-333. PubMed ID: 28295521
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period.
    Megna M; Napolitano M; Balato N; Monfrecola G; Villani A; Ayala F; Balato A
    Clin Exp Dermatol; 2016 Jul; 41(5):564-6. PubMed ID: 27028505
    [No Abstract]   [Full Text] [Related]  

  • 9. Onset of psoriatic arthritis during ustekinumab treatment for psoriasis: a case series of seven patients.
    Jones BB; Millsop JW; Walsh JA; Krueger GG; Callis Duffin K
    Br J Dermatol; 2015 Jul; 173(1):272-4. PubMed ID: 25557081
    [No Abstract]   [Full Text] [Related]  

  • 10. Severe dilated cardiomyopathy induced by adalimumab and ustekinumab.
    Membrillo de Novales FJ; Ávila Jiménez A; Merino Meléndez L; Torres León J; López Soberón E; Fe Marqués A; Pérez Mochales JF
    J Clin Rheumatol; 2015 Apr; 21(3):171-3. PubMed ID: 25807103
    [No Abstract]   [Full Text] [Related]  

  • 11. An analysis of Drug Survival, Effectiveness, and Safety in Moderate to Severe Psoriasis Treated With Ustekinumab: An Observational Study of 69 Patients in Routine Clinical Practice.
    Salgüero Fernández I; Gil MH; Sanz MS; Gullón GR
    Actas Dermosifiliogr (Engl Ed); 2019 Apr; 110(3):244-246. PubMed ID: 29961546
    [No Abstract]   [Full Text] [Related]  

  • 12. Psoriasis vulgaris complicated by eosinophilic pneumonia during ustekinumab treatment.
    Yashiro M; Maejima H; Taniguchi T; Katsuoka K; Kimura M; Wada M
    Eur J Dermatol; 2013; 23(3):396-7. PubMed ID: 23728153
    [No Abstract]   [Full Text] [Related]  

  • 13. Interstitial pneumonia in two patients with psoriasis during ustekinumab treatment.
    Kikuchi S; Umezawa Y; Hayashi M; Yanaba K; Fukuchi O; Ito T; Asahina A; Saeki H; Nakagawa H
    J Dermatol; 2016 Jun; 43(6):712-3. PubMed ID: 26703791
    [No Abstract]   [Full Text] [Related]  

  • 14. Multiple Clustered Dermatofibromas Following Ustekinumab Treatment for
    Ruiz-Villaverde R; Díaz-Martinez MA; Sánchez-Cano D
    Sultan Qaboos Univ Med J; 2017 Aug; 17(3):e375-e377. PubMed ID: 29062570
    [No Abstract]   [Full Text] [Related]  

  • 15. Bullous pemphigoid during ustekinumab therapy in a psoriatic patient.
    Onsun N; Sallahoglu K; Dizman D; Su Ö; Tosuner Z
    Eur J Dermatol; 2017 Feb; 27(1):81-82. PubMed ID: 27777186
    [No Abstract]   [Full Text] [Related]  

  • 16. Ustekinumab treatment in patients with psoriasis undergoing hemodialysis.
    Umezawa Y; Hayashi M; Kikuchi S; Fukuchi O; Yanaba K; Ito T; Asahina A; Saeki H; Nakagawa H
    J Dermatol; 2015 Jul; 42(7):731-4. PubMed ID: 25959602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug-induced interstitial lung disease (DILD) during treatment with ustekinumab].
    Sorger C; Simon JC; Treudler R
    Hautarzt; 2020 Apr; 71(4):309-312. PubMed ID: 31792580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab.
    Hesselvig JH; Egeberg A; Loft ND; Zachariae C; Kofoed K; Skov L
    Acta Derm Venereol; 2018 Mar; 98(3):335-339. PubMed ID: 29110019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab.
    Brunner PM; Conrad C; Vender R; Grond S; Schuster C; Patel H; Xu W; Carrascosa Carrillo JM
    Br J Dermatol; 2021 Oct; 185(4):865-867. PubMed ID: 34076896
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety of ustekinumab in adolescent patients with moderate-to-severe plaque psoriasis: real-world evidence from an ongoing European study (NCT03218488).
    Mahé E; Geldhof A; Jazra M; Bergmans P; Azzabi A; Seyger MMB
    J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):e646-e648. PubMed ID: 35349743
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.